Parabilis Medicines Completes Record Biotech IPO, Raising Up to $745 Million
Cancer-focused biotech Parabilis Medicines raised $670 million in its IPO — the largest in biotech history — with shares jumping as much as 67% on its first trading day after the offering priced above its marketed range. The company, formerly known as FogPharma, also completed a concurrent private placement bringing total proceeds to nearly $745 million, and plans to use the funds to advance its novel 'helicon peptide' drug platform targeting previously undruggable cancer pathways. The record-breaking listing signals renewed investor appetite for biotech IPOs following a drought in 2024.
Parabilis Medicines Inc. made its Nasdaq debut under the ticker 'PBLS,' raising $670 million through 33.5 million shares priced at $20 each — surpassing the previous biotech IPO record set just two months ago by Kailera Therapeutics at $625 million. Including a concurrent private placement, total proceeds reached approximately $745 million, and underwriters hold an option to purchase an additional 5 million shares that could add up to $100 million more. Shares surged as much as 67% on the first day of trading. The offering significantly exceeded the company's own revised expectations, having initially targeted $476 million in net proceeds before raising its guidance to $553 million earlier in the week. Parabilis, led by former Johnson & Johnson global R&D head Mathai Mammen, is developing helicon peptides — a novel drug class designed to engage targets long considered undruggable — with lead candidate zolucatetide targeting the Wnt/β-catenin pathway in desmoid tumors, familial adenomatous polyposis, and hepatocellular carcinoma. The company plans to allocate $150 million toward a Phase 3 trial in desmoid tumors, $120 million for ongoing Phase 1 trials, and $190 million to advance additional pipeline assets including ERG, AR, and β-catenin degraders.
What's missing
No clinical efficacy or safety data for lead candidate zolucatetide were cited across any source, leaving the scientific basis for investor confidence largely unaddressed.
How coverage differed
Bloomberg emphasized the stock's dramatic first-day trading performance and the combined IPO-plus-placement figure of $745 million, while Fierce Biotech and Yahoo Finance focused on the $670 million IPO gross proceeds as the record-setting figure and provided more detail on the company's pipeline and use of funds.
What different sources said
- Yahoo FinanceCenter
Parabilis now the largest VC-backed biotech IPO
- BloombergCenter
Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement
- Fierce BiotechCenter
Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs
Related
SpaceX IPO Makes Elon Musk World's First Trillionaire as Shares Surge 19% on Debut
SpaceX shares closed up 19% on their first trading day, pushing Elon Musk's net worth to approximately $1.11 trillion and making him the first individual in history to cross the trillion-dollar threshold. The company raised $75 billion at an IPO price of $135 per share, with shares closing near $161, giving SpaceX a market capitalization of roughly $2.1 trillion despite the company reporting a net loss of $4.94 billion in 2025. The milestone has drawn both investor enthusiasm and sharp criticism over Musk's social media conduct and concerns that the IPO's structure exploits passive index fund mechanics to extract wealth from ordinary retirement savers.
Delhi Power Bills to Rise for Some Consumers as Regulator Approves Higher Electricity Surcharge
Delhi's electricity regulator DERC has approved increased Power Purchase Adjustment Charges (PPAC) for distribution companies, raising bills for consumers in south, east, and central Delhi from July 2026. The hike follows a sharp rise in power procurement costs in April 2026, driven by higher summer demand and elevated fuel prices. The change also marks a structural shift from quarterly to monthly PPAC revisions, making electricity bills more responsive to real-time cost fluctuations.
SEC Proposes Repealing Rule 611 and Rule 610(e) of Regulation NMS
The Securities and Exchange Commission proposed on June 11, 2026, to rescind Rule 611 and Rule 610(e) of Regulation NMS, which govern trade-through protections and locking/crossing quotations in equity markets. Rule 611, in place for roughly two decades, requires trades to be executed at the best available price across exchanges. The proposal could reshape equity market structure and has implications for emerging areas such as tokenized stocks.